ADG116
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor
Trial Timeline
Aug 29, 2019 → Apr 27, 2021
NCT ID
NCT04111445About ADG116
ADG116 is a phase 1 stage product being developed by Adagene for Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT04111445. Target conditions include Solid Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04111445 | Phase 1 | Terminated |
Competing Products
20 competing products in Solid Tumor